EX-99.1 2 ex991to13g07422aeo_02192013.htm ex991to13g07422aeo_02192013.htm
Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated March 1, 2013 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
 
Dated:  March 1, 2013

BIOTECHNOLOGY VALUE FUND, L.P.
 
INVESTMENT 10, L.L.C.
 
 
     
By:
BVF Partners L.P., its general partner
 
By:
BVF Partners L.P., its investment manager
         
By:
BVF Inc., its general partner
 
By:
BVF Inc., its general partner
 
 
   
 
By:
/s/ Mark N. Lampert
 
By:
/s/ Mark N. Lampert
 
Mark N. Lampert
   
Mark N. Lampert
 
President
   
President
 
 
   
 
 
 
   
 
BIOTECHNOLOGY VALUE FUND II, L.P.
 
BVF PARTNERS L.P.
 
 
     
By:
BVF Partners L.P., its general partner
 
By:
BVF Inc., its general partner
By:
BVF Inc., its general partner
   
 
     
By:
/s/ Mark N. Lampert
By:
/s/ Mark N. Lampert
   
Mark N. Lampert
 
Mark N. Lampert
   
President
 
President
   
 
       
 
 
 
 
BVF INC.
 
 
   
 
BVF INVESTMENTS, L.L.C.
 
By:
/s/ Mark N. Lampert
       
Mark N. Lampert
By:
BVF Partners L.P., its manager
   
President
       
 
By:
BVF Inc., its general partner
   
 
 
 
   
 
By:
/s/ Mark N. Lampert
   
/s/ Mark N. Lampert
 
Mark N. Lampert
   
MARK N. LAMPERT
 
President